Annual Report

Overview

The report describes 2022 as transformative for the company after the RELEASE trial was terminated and the strategy shifted toward pre-clinical fimaNAC and fimaVACC research. The Group had 7 employees at year-end and mainly used external service providers for manufacturing, research and development, and regulatory work. It recorded no revenue in 2022, while other operating income amounted to NOK 4.8 million.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services